No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Beijing Chunlizhengda Medical Instruments Co., Ltd. functions as a prominent entity within the orthopedic medical device industry, dedicated to the development, manufacturing, and distribution of surgical implants, instruments, and associated medical supplies throughout the People's Republic of China. Its core product range features implantable orthopedic solutions, specifically comprising joint prostheses and spinal treatment products. The company predominantly distributes its merchandise via an expansive network of distributors, through original design manufacturing (ODM) and original equipment manufacturing (OEM) partnerships under the 'Chunli' label, and by direct sales to healthcare institutions. Beyond its domestic operations, the firm also engages in exporting its products to various countries globally. Established in 1998, its corporate headquarters are situated in Beijing, China.
www.clzd.comNo one on the platform currently holds 1858.HK.
No tracked institution reports a position in 1858.HK as of their last filing.
No one on the platform has traded 1858.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 17.3% | 20.6% | 38.3% | — | — | — |
| Rev. Growth % | 29.8% | 2.2% | ||||
| Profit Margin % | 26.1% | 23.9% | 25.2% | |||
| Free Cash Flow Margin % | 33.7% | 13.0% | 16.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | -0.5% | $0.80 | $0.80–$0.80 | — | 1 |
| 2027 | $1.3B | +20.1% | $1.00 | $1.00–$1.00 | — | 1 |
| 2028 | $1.6B | +17.8% | $1.19 | $1.19–$1.19 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-02-27 | $0.35 | $0.18 | -48.5% |
| 2024-10-30 | $0.21 | $-0.06 | -126.3% |
| $12.73 |
| -4.86% |
| $10.7B |
| — |
| 2190.HKZylox-Tonbridge Medical Technology Co., Ltd. | $20.44 | -1.35% | $6.4B | — |
| 2315.HKBiocytogen Pharmaceuticals (Beijing) Co., Ltd. | $57.00 | -4.12% | $23.1B | — |
Source: Financial Modeling Prep · peers by sector/industry